Sign up
Pharma Capital

Patrys' shares halted

The halt will remain in place until Monday 15th January 2018.
The company's shares are in pre-open

Patrys Ltd (ASX:PAB) has been granted a trading halt by the ASX this morning, pending details relating to managing its continuous disclosure obligations.

Patrys currently has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities.

The halt will remain in place until the opening of trade on Monday 15th January 2018, or earlier if an announcement is made to the market.

View full PAB profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.